tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Jagsonpal Pharma Publishes Unaudited Q3 and Nine-Month FY25 Results Extracts

Story Highlights
  • Jagsonpal Pharma has released newspaper extracts of unaudited financial results for Q3 and nine months ended December 2025.
  • The company notified BSE and NSE of this publication, underscoring regulatory compliance and transparency to investors.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Jagsonpal Pharma Publishes Unaudited Q3 and Nine-Month FY25 Results Extracts

Claim 50% Off TipRanks Premium

Jagsonpal Pharmaceuticals Ltd. ( (IN:JAGSNPHARM) ) has shared an update.

Jagsonpal Pharmaceuticals Ltd. has published newspaper advertisements in the English and Hindi editions of Business Standard containing extracts of its unaudited financial results for the quarter and nine-month period ended 31 December 2025, in compliance with Regulation 47 of SEBI’s Listing Obligations and Disclosure Requirements. By formally notifying the stock exchanges of this disclosure, the company is reinforcing its regulatory compliance and transparency obligations to investors and other stakeholders regarding its interim financial performance.

More about Jagsonpal Pharmaceuticals Ltd.

Jagsonpal Pharmaceuticals Ltd. is an Indian pharmaceutical company operating in the healthcare industry, with its shares listed on both BSE and the National Stock Exchange of India under the symbol JAGSNPHARM. The company is subject to SEBI’s Listing Obligations and Disclosure Requirements, reflecting its status as a publicly traded entity in the domestic capital markets.

Average Trading Volume: 3,732

Technical Sentiment Signal: Hold

Current Market Cap: 11.64B INR

For an in-depth examination of JAGSNPHARM stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1